Skip to main content

Table 4 Clinical trials evaluating WEE1/PKMYT1 inhibitor in monotherapy or in combination for cancer therapy

From: A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target

Study ID Study title Tumor Interventions Status Phase
NCT02610075 Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. S AZD1775 C 1
NCT03668340 AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma S AZD1775 R 2
NCT02482311 Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours S AZD 1775 C 1
NCT02207010 A Phase 0 Study of AZD1775 in Recurrent GBM Patients S AZD1775 NA 1
NCT03315091 Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours S AZD1775 C 1
NCT01748825 AZD1775 for Advanced Solid Tumors S/H AZD1775 ANR 1
NCT02511795 AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors S AZD1775 + Olaparib C 1
NCT03313557 AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies S AZD1775 C 1
NCT02593019 Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients S AZD1775 NA 2
NCT02688907 Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation S AZD1775 T 2
NCT02087176 A Placebo Controlled Study Comparing AZD1775 + Docetaxel Versus Placebo + Docetaxel to Treat Lung Cancer S AZD1775 + Docetaxel T 2
NCT03012477 CISPLATIN + AZD-1775 In Breast Cancer S AZD1775 + Cisplatin ANR 2
NCT02341456 Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours S AZD1775 + Carboplatin or Paclitaxel C 1
NCT02791919 Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia H AZD1775 + Cytarabine or Filgrastim or Fludarabine Phosphate W 1
NCT02513563 AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer S AZD1775 + Carboplatin or Paclitaxel R 2
NCT03718143 AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis H AZD1775 + Cytarabine T 2
NCT02585973 Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC S AZD1775 + Cisplatin + Radiation R 1
NCT02087241 Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer S AZD1775 + pemetrexed or carboplatin T 2
NCT02381548 Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia H AZD1775 + Belinostat T 1
NCT03333824 Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer S AZD1775 C 1
NCT02906059 Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer S AZD1775 + Irinotecan R 1
NCT02037230 Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas S AZD1775 + Gemcitabine+ Radiation Therapy C 1,2
NCT02617277 Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours S AZD1775 + Durvalumab ANR 1
NCT02666950 WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome H AZD1775 + Cytarabine C 2
NCT01047007 A Dose Escalation Study of MK1775 in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005) S AZD1775 + 5-FU or 5-FU/CDDP T 1
NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer S AZD1775 + carboplatin NA 2
NCT02448329 Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy S AZD1775 + paclitaxel R 2
NCT02508246 WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck S AZD1775 + Cisplatin + Docetaxel C 1
NCT03253679 AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification S AZD1775 R 2
NCT01076400 A Study of MK-1775 in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008) S AZD1775 + Topotecan or Cisplatin T 1,2
NCT02196168 Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer S AZD1775 +Cisplatin T 2
NCT02101775 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer S AZD1775 + Gemcitabine ANR 2
NCT03028766 WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer S AZD1775 + Cisplatin + Radio therapy ANR 1
NCT01357161 A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) S AZD1775 + paclitaxel + carboplation C 2
NCT03284385 Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 S AZD1775 R 2
NCT00648648 A Dose Escalation Study of MK-1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001) S AZD1775 + Gemcitabine or Cisplatin or Carboplatin C 1
NCT02194829 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery S AZD-1775 + Gemcitabine + paclitaxel ANR 1,2
NCT02576444 Olaparib Combinations S AZD1775 + olaparib ANR 2
NCT04197713 Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study S AZD1775 + olaparib ANR 1
NCT01922076 Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas S AZD1775 + Radiation Therapy ANR 1
NCT03579316 Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer S AZD1775 + olaparib R 2
NCT02095132 Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors S AZD1775 + Irinotecan or Irinotecan Hydrochloride R 1,2
NCT03345784 Adavosertib, External Beam Radiation Therapy, and Cisplatin in Treating Patients With Cervical, Vaginal, or Uterine Cancer S AZD1775 +Cisplatin + Radiation (External Beam Radiation Therapy) R 1
NCT01849146 Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma S AZD1775 + Radiation Therapy + Temozolomide R 1
NCT02937818 A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer S AZD1775 + carboplatin ANR 2
NCT02546661 Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer S AZD1775 + Durvalumab ANR 1
NCT02659241 Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer S AZD1775 R 1
NCT02272790 Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer S AZD1775 + Paclitaxel or Carboplatin or Gemcitabine or pegylated liposomal doxorubicin ANR 2
NCT02813135 European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors S/H AZD1775 + carboplatin R 1,2
NCT03330847 To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. S AZD1775 + olaparib R 2
NCT01827384 MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations S AZD1775 + carboplatin R 2
NCT02465060 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) S/H AZD1775 R 2
  1. S solid tumor, H hematological tumor, C completed, R recruiting, W withdraw, ANR active not recruiting, T terminated, NA status unknown (last update 04/22/2020)